BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 30303537)

  • 1. Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.
    Girard E; Eon-Marchais S; Olaso R; Renault AL; Damiola F; Dondon MG; Barjhoux L; Goidin D; Meyer V; Le Gal D; Beauvallet J; Mebirouk N; Lonjou C; Coignard J; Marcou M; Cavaciuti E; Baulard C; Bihoreau MT; Cohen-Haguenauer O; Leroux D; Penet C; Fert-Ferrer S; Colas C; Frebourg T; Eisinger F; Adenis C; Fajac A; Gladieff L; Tinat J; Floquet A; Chiesa J; Giraud S; Mortemousque I; Soubrier F; Audebert-Bellanger S; Limacher JM; Lasset C; Lejeune-Dumoulin S; Dreyfus H; Bignon YJ; Longy M; Pujol P; Venat-Bouvet L; Bonadona V; Berthet P; Luporsi E; Maugard CM; Noguès C; Delnatte C; Fricker JP; Gesta P; Faivre L; Lortholary A; Buecher B; Caron O; Gauthier-Villars M; Coupier I; Servant N; Boland A; Mazoyer S; Deleuze JF; Stoppa-Lyonnet D; Andrieu N; Lesueur F
    Int J Cancer; 2019 Apr; 144(8):1962-1974. PubMed ID: 30303537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
    Shahi RB; De Brakeleer S; Caljon B; Pauwels I; Bonduelle M; Joris S; Fontaine C; Vanhoeij M; Van Dooren S; Teugels E; De Grève J
    BMC Cancer; 2019 Apr; 19(1):313. PubMed ID: 30947698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene.
    Fostira F; Kostantopoulou I; Apostolou P; Papamentzelopoulou MS; Papadimitriou C; Faliakou E; Christodoulou C; Boukovinas I; Razis E; Tryfonopoulos D; Barbounis V; Vagena A; Vlachos IS; Kalfakakou D; Fountzilas G; Yannoukakos D
    J Med Genet; 2020 Jan; 57(1):53-61. PubMed ID: 31300551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer.
    Hauke J; Horvath J; Groß E; Gehrig A; Honisch E; Hackmann K; Schmidt G; Arnold N; Faust U; Sutter C; Hentschel J; Wang-Gohrke S; Smogavec M; Weber BHF; Weber-Lassalle N; Weber-Lassalle K; Borde J; Ernst C; Altmüller J; Volk AE; Thiele H; Hübbel V; Nürnberg P; Keupp K; Versmold B; Pohl E; Kubisch C; Grill S; Paul V; Herold N; Lichey N; Rhiem K; Ditsch N; Ruckert C; Wappenschmidt B; Auber B; Rump A; Niederacher D; Haaf T; Ramser J; Dworniczak B; Engel C; Meindl A; Schmutzler RK; Hahnen E
    Cancer Med; 2018 Apr; 7(4):1349-1358. PubMed ID: 29522266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hereditary truncating mutations of DNA repair and other genes in BRCA1/BRCA2/PALB2-negatively tested breast cancer patients.
    Lhota F; Zemankova P; Kleiblova P; Soukupova J; Vocka M; Stranecky V; Janatova M; Hartmannova H; Hodanova K; Kmoch S; Kleibl Z
    Clin Genet; 2016 Oct; 90(4):324-33. PubMed ID: 26822949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
    Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
    Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
    Nurmi A; Muranen TA; Pelttari LM; Kiiski JI; Heikkinen T; Lehto S; Kallioniemi A; Schleutker J; Bützow R; Blomqvist C; Aittomäki K; Nevanlinna H
    Int J Cancer; 2019 Nov; 145(10):2692-2700. PubMed ID: 30927251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].
    Pohlreich P; Kleibl Z; Kleiblová P; Janatová M; Soukupová J; Macháčková E; Házová J; Vašíčková P; Sťahlová Hrabincová E; Navrátilová M; Svoboda M; Foretová L
    Klin Onkol; 2012; 25 Suppl():S59-66. PubMed ID: 22920209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene Panel Testing in Hereditary Breast Cancer.
    Rostami P; Zendehdel K; Shirkoohi R; Ebrahimi E; Ataei M; Imanian H; Najmabadi H; Akbari MR; Sanati MH
    Arch Iran Med; 2020 Mar; 23(3):155-162. PubMed ID: 32126783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing.
    Dominguez-Valentin M; Nakken S; Tubeuf H; Vodak D; Ekstrøm PO; Nissen AM; Morak M; Holinski-Feder E; Holth A; Capella G; Davidson B; Evans DG; Martins A; Møller P; Hovig E
    Sci Rep; 2019 Dec; 9(1):18555. PubMed ID: 31811167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
    Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
    Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-exome sequencing of Finnish hereditary breast cancer families.
    Määttä K; Rantapero T; Lindström A; Nykter M; Kankuri-Tammilehto M; Laasanen SL; Schleutker J
    Eur J Hum Genet; 2016 Jan; 25(1):85-93. PubMed ID: 27782108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: an Italian case-control study.
    Bucalo A; Conti G; Valentini V; Capalbo C; Bruselles A; Tartaglia M; Bonanni B; Calistri D; Coppa A; Cortesi L; Giannini G; Gismondi V; Manoukian S; Manzella L; Montagna M; Peterlongo P; Radice P; Russo A; Tibiletti MG; Turchetti D; Viel A; Zanna I; Palli D; Silvestri V; Ottini L
    Eur J Cancer; 2023 Jul; 188():183-191. PubMed ID: 37262986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
    Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J
    Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline investigation in male breast cancer of DNA repair genes by next-generation sequencing.
    Scarpitta R; Zanna I; Aretini P; Gambino G; Scatena C; Mei B; Ghilli M; Rossetti E; Roncella M; Congregati C; Bonci F; Naccarato AG; Palli D; Caligo MA
    Breast Cancer Res Treat; 2019 Dec; 178(3):557-564. PubMed ID: 31512090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer.
    Neidhardt G; Hauke J; Ramser J; Groß E; Gehrig A; Müller CR; Kahlert AK; Hackmann K; Honisch E; Niederacher D; Heilmann-Heimbach S; Franke A; Lieb W; Thiele H; Altmüller J; Nürnberg P; Klaschik K; Ernst C; Ditsch N; Jessen F; Ramirez A; Wappenschmidt B; Engel C; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
    JAMA Oncol; 2017 Sep; 3(9):1245-1248. PubMed ID: 28033443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of Pathogenic Germline Mutations in Early and Late Onset Familial Breast Cancer Patients Using Multi-Gene Panel Sequencing: An Egyptian Study.
    Nassar A; Zekri AN; Kamel MM; Elberry MH; Lotfy MM; Seadawy MG; Hassan ZK; Soliman HK; Lymona AM; Youssef ASE
    Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
    Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR
    Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.